Neuropeptide Y (NPY) activates the sympathetic and vagal nervous systems through the Y1 and
Y2 receptors. This double-blind placebo-controlled crossover study investigated the
sympathovagal balance during three exercises on a cycloergometer in healthy volunteers
treated with saxagliptin (DPP4 inhibitor).